Weight Loss
FDA Approved
Approved
Tirzepatide
Mounjaro / Zepbound
Dual GIP/GLP-1 agonist with up to 22.5% weight reduction reported in SURMOUNT-1.
Quick Facts
Amino Acids
39
Route
subcutaneous
Evidence
FDA Approved
FDA Status
Approved
Mechanism of Action
Dual GIP/GLP-1 receptor agonist -- activates both incretin pathways for enhanced metabolic effects